Before the disruption in the clinic of immune checkpoint inhibitors (ICI), early immunotherapy efforts focused on harnessing the immune system using cytokines, such as interleukin-2 (IL-2) and interferon-alfa (IFN-α) in patients with melanoma and renal cancer [1,2,3,4]. The gene discussed is IL2; the disease is renal carcinoma.